The Social Innovation

Simon and Jane Berry founded ColaLife with the goal of transforming access to life-saving diarrhoea treatment in Sub-Saharan Africa, starting with Zambia.  

ColaLife’s innovation is the Kit Yamoyo: an affordable, aspirational anti-diarrhoea kit containing co-packaged Oral Rehydration Salts (ORS) and Zinc, designed for easy use and distribution through both public and private channels.  

The model leverages value chain thinking and human-centered design to overcome barriers to access, with a focus on creating demand and profitability at every step - inspired by the Coco-Cola value chain.

For distribution, given the demand and need, ColaLife was able to leverage existing retail and public sector distribution channels, moving beyond their initial idea of simply “piggybacking” on Coca-Cola crates. Given the high need, the companies and public sector partners were game to include their product in their delivery channels, which helped expand the reach.

During a trial in 2012/13, 26,000 kits were sold in rural Zambia in just one year, raising the correct treatment rate for diarrhoea in the trial areas from less than 1% to 45%. After the trial, ColaLife assisted with a national scale-up until 2018 when all external assistance came to an end.

To help quantify ColaLife’s legacy an analysis was done 4.5 years after withdrawal. This found that during the seven years of ColaLife’s involvement, 760,000 kits were distributed. In the 4.5 years since withdrawal a further 1.1 million kits had left the local manufacturer’s factory. Today, 85% of these kits are distributed free of charge via government clinics. 

Magnitude of the Problem, and its Root Causes

Each year, approximately 300,000 children die from diarrhoea in Sub-Saharan Africa, yet less than 1% of these children receive the recommended treatment of Oral Rehydration Salts (ORS) combined with Zinc. Additionally, 40% of children under the age of five in the region are stunted, with diarrhoea being a major contributing factor.  

During their participation in the Globalizer co-created by Ashoka and Philips Foundation in 2016, ColaLife highlighted the following key factors contributing to the magnitude of the problem:

  • Poor access to ORS and Zinc (distance, cost, supply chain gaps)
  • Lack of awareness about the co-packing of ORS-Zinc and hence lesser demand among caregivers
  • Public sector systems strained; private sector underutilized
  • Product design not suited to local needs (e.g., 1L sachets impractical)
  • Policy inertia and lack of local manufacturing

Based on their systems change analysis, the ColaLife team made it their mission to build a sustainable market for a better designed and distributed ORS/Zinc co-pack to tackle the inaccessibility and lack of awareness.

The Globalizer was very valuable because it took us through that detailed thought process and actually made us realise, hang on, we don’t think we can do this or... we don’t think it’s the right approach.

Strategy to Catalyze a Network of Changemakers towards the Targeted Mission

The ColaLife team realized that country-by-country replication would not achieve the desired scale or sustainability and shifted its strategy to influence a global policy within the most influential player in the system - the World Health Organization.  

Some of the tactics they deployed towards the mission as a part of the strategy include:

1) Co-created, with the Diarrhoea Innovations Group (DIG), a pitch to the WHO to include ORS-Zinc in their Essential Medicines List

After piloting and scaling Kit Yamoyo in Zambia, ColaLife realized that the most effective way to build the co-pack market to address the inaccessibility and lack of awareness was to change the global standard of care.  

We weren’t interested in globalising our organisation. We were interested in globalising our impact.   
Our organisation and the methodology that we developed was best applied to trying to change the system at global level. So instead of going, you know, country by country repeating what we’d done in Zambia. We decided that the best way was to try and get co-packaged ORS and zinc on the WHO essential medicines list.

They identified that influencing the WHO Essential Medicines List (EML) as the most impactful strategy, since many countries base their national lists and procurement on the WHO EML.

To pursue this, ColaLife approached the Diarrhoea Innovations Group (DIG), a global network of technical experts, researchers, and practitioners focused on improving diarrhoea treatment and prevention. They made a compelling case to DIG that, beyond technical innovation, there was a critical need to advocate for policy change—specifically, to get co-packaged ORS and Zinc recognized as the global standard for diarrhoea treatment.

DIG, with its broad membership and technical credibility, was well-positioned to support this effort. By pooling expertise and resources, the group prepared a formal application to the WHO to add co-packaged ORS and Zinc to the Essential Medicines List. This process required assembling scientific evidence, demonstrating public health need, and building consensus among global health stakeholders.  

The application had 15 named authors and was successful. In 2019: the WHO updated its Essential Medicines List to include co-packaged ORS and Zinc for the treatment of childhood diarrhoea.  

This policy change was significant because, although the EML is not legally binding in any way, it strongly influences national health policies and procurement decisions across different countries.  

2) Co-created ORSZCA to Involve Players to Accelerate the Uptake of ORS/Zinc by National Governments 

Following the inclusion of co-packaged ORS and Zinc in the WHO Essential Medicines List, the ORS/Zinc Co-pack Alliance (ORSZCA) was formed as an informal global network with the aim on accelerating the uptake of the new guidance by national governments and those working in partnership with them.  

ORSZCA had a mailing list of 250 members across countries which would support data collection and monitor progress of the uptake.  

By the end of 2024 at least 3 governments including Ethiopia, Madagascar and Pakistan have added co-packaged ORS-Zinc to their national essential medicines lists.  

In December 2024, due to resource constraints, ORSZCA was dissolved and its function was moved to the Child Health Task Force

simon
simon
Date:
Author:
Akash Bhalerao
Reviewers:
Jane Berry, Yeleka Barrett, Simon Berry, Santiago Del Giudice, Nadine Freeman
Story Structure & Design Contributors:
Maria Zapata Diana Wells Rohan Suseelan Olga Shirobokova Florentine Roth Mi Nguyen Odin Muehlenbein Madhavi Malgaonkar Jayalakshmi Jayanth Nadine Freeman Antonio Fernandez Michela Fenech Santiago Del Giuduce Ovidiu Hristu Condurache Pablo Carranza Tatiana Carey Ina Bogdanova Akash Bhalerao
Ashoka Strategy Facilitators during the Program:
Odin Muehlenbein, Michela Fenech